文献速递间质性肺疾病

携带表面活性物质相关基因突变的成人肺纤维化患者疾病进展与低生存率:一项观察性研究

Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study.
PubMed 文献 · Chest · 2022-11-09

SRG突变组诊断时更年轻、男性更少,但FVC(72%预计值)和DLCO(46%预计值)更低;中位无移植生存44个月,与FPF或sIPF无差异。抗纤维化治疗6个月的7例患者FVC中位变化+40 mL,而免疫调节治疗反应因基因而异。

要点

  • SRG突变相关ILD患者诊断时肺功能更差,中位无移植生存仅44个月。
  • SRG突变组FVC下降速度与FPF和sIPF相似,但治疗期间FVC下降更显著。
  • 抗纤维化治疗6个月的部分SRG突变患者FVC稳定(中位+40 mL)。

核心结论

  • 携带SRG突变的ILD患者肺功能进行性下降,生存率严重降低,尽管治疗可能存在获益。

研究设计与样本

  • 对照组包括248例家族性肺纤维化(FPF)患者和575例散发性特发性肺纤维化(sIPF)患者。

主要发现

  • SRG突变组诊断时中位年龄45岁,男性11例,FVC中位72%预计值,DLCO中位46%预计值。
  • SRG突变组诊断后6个月FVC中位下降-40 mL,中位无移植生存44个月,与FPF或sIPF组无差异。
  • SRG突变组接受免疫调节或抗纤维化治疗期间FVC下降较未治疗者显著更大。
  • SRG突变组中7例接受抗纤维化治疗6个月的患者FVC中位变化+40 mL(四分位距-40至90 mL)。
  • SRG突变组接受免疫调节治疗的患者反应因涉及基因而异。

临床怎么用

  • 对年轻、男性少但肺功能差的ILD患者,应考虑SRG突变检测。
  • SRG突变相关ILD患者抗纤维化治疗可能稳定肺功能,免疫调节治疗需根据基因个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In some patients with progressive fibrosing interstitial lung disease (ILD), disease is caused by carriage of a mutation in a surfactant-related gene (SRG) such as SFTPC, SFTPA2, or ABCA3. However, no aggregated data on disease evolution and treatment outcome have been presented for these patients. RESEARCH QUESTION: In adult patients with ILD with an SRG mutation, what is the course of lung function after diagnosis and during treatment and the survival in comparison with patients with sporadic idiopathic pulmonary fibrosis (sIPF) and familial pulmonary fibrosis (FPF)? STUDY DESIGN AND METHODS: We retrospectively examined the clinical course of a cohort of adults with an SRG mutation by screening 48 patients from 20 families with an SRG mutation for availability of clinical follow-up data. For comparison, 248 patients with FPF and 575 patients with sIPF were included. RESULTS: Twenty-three patients with ILD (median age: 45 years; 11 men) with an SRG mutation fulfilled criteria. At diagnosis, patients with an SRG mutation were younger and less often male, but had lower FVC (72% predicted) and diffusing capacity of the lungs for carbon monoxide (46% predicted) compared with patients with FPF or sIPF. In the SRG mutation group, median FVC decline 6 months after diagnosis was -40 mL and median transplant-free survival was 44 months and not different from patients with FPF or sIPF. FVC course was not different among the three cohorts; however, a significantly larger decrease in FVC was found while patients received immunomodulatory or antifibrotic treatment compared with those receiving no treatment. Subsequent analysis in the SRG group showed that patients with a surfactant mutation (n = 7) treated for 6 months with antifibrotic drugs showed stable lung function with a median change in FVC of +40 mL (interquartile range, -40 to 90 mL), whereas patients with an SRG mutation treated with immunomodulatory drugs showed a variable response dependent on the gene involved. INTERPRETATION: This study showed that patients with ILD carrying an SRG mutation experience progressive loss of lung function with severely reduced survival despite possible beneficial effects of treatment.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Klay D, Grutters JC, van der Vis JJ, et al. Progressive Disease With Low Survival in Adult Patients With Pulmonary Fibrosis Carrying Surfactant-Related Gene Mutations: An Observational Study. Chest. 2022. PMID: 36370864. doi:10.1016/j.chest.2022.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。